StoxSun Pharmaceutical Industries vs Divi's Laboratories: share price & financials comparison
NSE: SUNPHARMA vs DIVISLAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sun Pharmaceutical Industries vs Divi's Laboratories at a glance
Sun Pharmaceutical Industries (SUNPHARMA) has a market capitalisation of ₹4,46,270 Cr, against ₹2,73,493 Cr for Divi's Laboratories (DIVISLAB). Over the past year Divi's Laboratories has returned +58.5%, compared with +8.4% for Sun Pharmaceutical Industries. On valuation, Sun Pharmaceutical Industries trades at a lower P/E of 40.7 versus 93.5. Divi's Laboratories earns a higher return on equity (17.5% vs 12.3%). Sun Pharmaceutical Industries comes out ahead on size and valuation. Divi's Laboratories comes out ahead on profitability, growth, momentum and technicals. Across the scored metrics below, Sun Pharmaceutical Industries leads on 5 and Divi's Laboratories on 12. On StoxGud's 10-point checklist, Sun Pharmaceutical Industries scores 8/10 and Divi's Laboratories scores 8/10.
| Metric | Sun Pharmaceutical Industries | Divi's Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹4,46,270 Cr | ₹2,73,493 Cr |
| Revenue (latest FY) | ₹58,462 Cr | ₹10,560 Cr |
| Net profit (latest FY) | ₹11,479 Cr | ₹2,568 Cr |
| Valuation | ||
| P/E | 40.7 | 93.5 |
| P/B | 5.00 | 16.32 |
| Dividend yield | 0.88% | 0.29% |
| Profitability | ||
| Return on equity | 12.3% | 17.5% |
| Net profit margin | 17.8% | 26.0% |
| Operating margin | 29.3% | 35.3% |
| Growth | ||
| Revenue growth (YoY) | +11.9% | +27.8% |
| Net profit growth (YoY) | -36.2% | +65.5% |
| Revenue CAGR (multi-year) | +11.8% | +11.8% |
| Financial health | ||
| Debt to equity | 0.03 | 0.00 |
| Momentum | ||
| 1-month return | +4.4% | +7.6% |
| 1-year return | +8.4% | +58.5% |
| 3-year CAGR | +17.4% | +43.3% |
| 5-year CAGR | +18.4% | +16.1% |
| 10-year CAGR | +11.0% | +23.3% |
| Distance from 52W high | -7.1% | +0.0% |
| Technicals | ||
| RSI (14) | 77 | 82 |
| Price vs 200-day avg | +2.7% | +39.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sun Pharmaceutical Industries | Divi's Laboratories |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sun Pharmaceutical Industries or Divi's Laboratories?
Sun Pharmaceutical Industries has a market cap of ₹4,46,270 Cr and Divi's Laboratories has a market cap of ₹2,73,493 Cr as of 06 Nov 2026.
Which has a lower P/E, Sun Pharmaceutical Industries or Divi's Laboratories?
Sun Pharmaceutical Industries has the lower P/E: Sun Pharmaceutical Industries trades at 40.7 and Divi's Laboratories at 93.5.
Which gave better returns in the last year, Sun Pharmaceutical Industries or Divi's Laboratories?
Divi's Laboratories did better: Sun Pharmaceutical Industries returned +8.4% and Divi's Laboratories returned +58.5% over one year.
Is Sun Pharmaceutical Industries or Divi's Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Sun Pharmaceutical Industries scores 8/10 and Divi's Laboratories scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.